Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Stephen Lash, PharmD
Advertisement
Articles by Stephen Lash, PharmD
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
February 1st 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
5